Last updated: 2026-10-20 07:29:00. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
SL Science Holding Limited (SLBT) operates in the -- sector and is listed on NASDAQ. The stock is currently priced at $1.54, with a market capitalization of $857.96M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1.42 to $14.50. This page covers its latest market performance, valuation, price trends and company information.
$857.96M | |
$1.49 | |
$53.95 | |
$1.42 | |
$1.53 | |
12.04K | |
78.48K | |
-- | |
$14.50 | |
$1.42 | |
-- | |
-- |
SL Science Holding Limited (SLBT) last closed at $1.53 as of 2026-10-19 23:31:00, unchanged from the previous close of $1.53.
During the latest regular trading session, SLBT traded between $1.42 and $53.95, with a volume of 12.04K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, SL Science Holding Limited (SLBT) moved from $1.51 to $1.54, representing a gain of 1.99% ($0.03).
The stock traded between $1.47 and $1.75 during the period. The latest price is near the lower end of the 7-day range, indicating moderate upward.
The average daily volume was 52.86 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 0.9%
SLBT is currently trading at $1.54, placing it 0.9% of the way from its 52-week low of $1.42 to its 52-week high of $14.50. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
SL Science Holding Ltd is a biomedical company specialized in developing cellular and gene therapies advancing regenerative medicine and cancer treatment. It utilizes immune stem cells to target cancer and bovine-derived milk exosomes to regenerate damaged tissues, thus potentially offering expansive medical applications for its products. With proprietary technologies such as Armed-T and Gamma Delta T cells, as well as exosome applications in skincare and cancer recovery. It operates in three segments namely Exosome products, CD-19 Armed-T products, and GDT cell therapy products. It derives revenue from Exosome products segment.
| Employees | 20 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of SL Science Holding Limited (SLBT) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.